Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? (Q81825135)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

Juris J Meier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Michael A Nauck

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

26 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Endocrinology and Metabolism

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

606-607

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0946

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0946

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18725906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference